Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?

International Journal of Dermatology

Volumn 48, Issue 11, 2009, Pages 1250-1253

  Wollina, U ^a   Kostler E ^a   Koch, A ^a   Riedel, H ^b   Stolzel U ^c  

^a Department of Dermatology and Allergology ^*  (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Klinik für Innere Medizin des Klinikums Chemnitz   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE;

ARTICLE; CHEMICAL ANALYSIS; DISEASE SEVERITY; ELECTRON MICROSCOPY; FECES ANALYSIS; FEMALE; HEMOCHROMATOSIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER HEMOSIDEROSIS; LIVER INJURY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PORPHYRIA CUTANEA TARDA; RELAPSE; REMISSION; URINALYSIS;

ANTIMALARIALS; BIOPSY; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOSIDEROSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LIVER; MALE; MEMBRANE PROTEINS; PORPHYRIA CUTANEA TARDA; SEVERITY OF ILLNESS INDEX;

EID: 70449377208     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04205.x     Document Type: Article

References (16)

1. Stölzel U, Köstler E, Schuppan D. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003, 129:309-313.
2. Kratka K, Dostalikova-Cimburova M, Michalikova H. High prevalence of HFE gene mutations in patients with porphyria cutanea tarda in the Czech Republic. Br J Dermatol 2008, 159:585-590.
3. Sebastiani G, Walker AP. HFE gene in primary and secondary hepatic iron overload. World J Gastroenterol 2007, 13:4673-4689.
4. Siersema PD, Rademakers LHPM, Cleton MI. The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda: the role of irons. J Hepatol 1995, 23:259-267.
5. Kappas A, Sassa S, Galbright RA, Nordman Y, Sciver CR, Beaude AL, Sly WS, Valle D. The porphyrias. The Molecular Basis of Inherited Disease 1995, 2103-2160. In, eds, 7th edn, New York, NY, McGraw-Hill Co.
6. Kordac V, Semradova M. Treatment of porphyria cutanea tarda with chloroquine. Br J Dermatol 1974, 90:95-100.
7. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007, 20:160-174.
8. Köstler E, Pollack P, Seebacher C, Riedel H. Iron metabolism and chloroquine phosphate therapy in porphyria cutanea tarda [German]. Z Hautkr 1990, 65:1030-1035.
9. Lundvall O. The effect of phlebotomy therapy in porphyria cutanea tarda. Its relation to the phlebotomy-induced reduction of iron stores. Acta Med Scand 1971, 189:33-49.
10. Riedel H, Justus J, Köstler E. Zur Morphologie des Leberschadens bei der chronischen hepatischen Porphyrie unter besonderer Berücksichtigung des Therapieeffektes. Pathologe 1984, 5:216-225.
11. Kemmer C, Riedel H, Köstler E, Pätzold K. Zur Bedeutung parakristalliner Nadelstrukturen für die Diagnose der chronischen hepatischen Porphyrie - licht- und elektronenmikroskopische Untersuchungen an Biopsiematerial. Zentralbl Allg Pathol 1983, 127:253-264.
12. Tannapfel A, Stölzel U, Köstler E. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch 2001, 439:1-5.
13. Dereure O, Jumez N, Bessis D. Measurement of liver iron content by magnetic resonance imaging in 20 patients with overt porphyria cutanea tarda before phlebotomy therapy: a prospective study. Acta Derm Venereol 2008, 88:341-345.
14. Rossmann-Ringdahl I, Olsson R. Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment. Acta Derm Venereol 2007, 87:401-405.
15. Köstler E, Wollina U. Therapy of porphyria cutanea tarda. Expert Opin Pharmacother 2005, 6:377-383.
16. Kordac V. Frequency of occurrence of hepatocellular carcinoma in patients with porphyria cutanea tarda in long-term follow-up. Neoplasma 1972, 19:135-139.